Fitzsimons R, Greenberger P A, Patterson R
J Allergy Clin Immunol. 1986 Aug;78(2):349-53. doi: 10.1016/s0091-6749(86)80088-4.
We report on the outcome of 56 pregnancies in 51 women with severe asthma requiring prednisone and/or beclomethasone dipropionate. There were no malformations, neonatal deaths, or maternal deaths. The overall incidence of premature (less than 37 weeks gestational age) and low birth-weight infants (less than or equal to 2500 gr) was slightly higher than would be expected in the general population. These findings appeared attributable in part to infants of gravidas whose asthma was complicated by emergency room visits or status asthmaticus. There was a statistically increased incidence of low birth weight and small size for gestational age infants in the eight infants born to women who experienced status asthmaticus when these infants were compared to the 41 infants born to women who did not require emergency room therapy or develop status asthmaticus. Our data confirm that prednisone and beclomethasone dipropionate are appropriate therapy for pregnant women with severe asthma and suggest that the prevention of status asthmaticus may result in a favorable outcome for the fetus. The current study confirms previous evaluations of pregnant women with severe asthma conducted by Northwestern University Allergy Service and extends the series to 171 pregnancies.
我们报告了51名患有严重哮喘且需要泼尼松和/或二丙酸倍氯米松治疗的女性的56次妊娠结局。未出现畸形、新生儿死亡或孕产妇死亡情况。早产（孕周小于37周）和低体重儿（体重小于或等于2500克）的总体发生率略高于一般人群的预期。这些发现部分似乎归因于哮喘合并急诊就诊或哮喘持续状态的孕妇所生的婴儿。与41名未需要急诊治疗或未发生哮喘持续状态的女性所生的婴儿相比，经历过哮喘持续状态的女性所生的8名婴儿中，低体重儿和小于胎龄儿的发生率在统计学上有所增加。我们的数据证实，泼尼松和二丙酸倍氯米松是治疗重度哮喘孕妇的合适药物，并表明预防哮喘持续状态可能会给胎儿带来良好结局。本研究证实了西北大学过敏科先前对重度哮喘孕妇的评估，并将该系列研究扩展至171次妊娠。
